<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="antiviral1\PMC7120516\results\search\drugs\results.xml">
  <result pre="from the substrate envelope. Similarly prolonged therapy against HBV with" exact="lamivudine" post="is associated with an increased incidence of viral resistance."/>
  <result pre="reduces viral burden in chronic HBV carriers. Long-term treatment with" exact="lamivudine" post="may, however, lead to resistance as the result of"/>
  <result pre="RNA-dependent DNA polymerase activity. It has similar therapeutic effects to" exact="lamivudine" post="and is responsible for the emergence of mutants usually"/>
  <result pre="B domain of the polymerase gene. However, mutants resistant to" exact="famciclovir" post="appear to be less common than those induced by"/>
  <result pre="famciclovir appear to be less common than those induced by" exact="lamivudine" post="(Pichoud et al. 1999). The X gene protein exhibits"/>
  <result pre="or antiviral nucleoside/nucleotide analogues such as lamivudine, adefovir dipivoxil, and" exact="ribavirin" post="(Marcellin et al. 2002; Chander et al. 2002) and"/>
  <result pre="et al. 2002; Chander et al. 2002) and IFN or" exact="lamivudine" post="alone can control hepatitis B in about one-third of"/>
  <result pre="et al. 2002; Liaw 2002). A combination of IFN with" exact="ribavirin" post="is standard therapy for hepatitis C and has resulted"/>
  <result pre="Liver diseases severity increases in C and D IFN and" exact="ribavirin" post="Farci and Purcell (2000) Genotype 1 and genotype 2"/>
  <result pre="via the JAK–STAT pathway; IFN-alpha-induced genes with antiviral properties, including" exact="adenosine" post="deaminase/eukaryotic translation initiation factor 2A-alpha kinase 2/NFKB1/myxovirus resistance 1/2′5′-oligoadenylate"/>
  <result pre="excellent agreement; 0.4 &amp;lt; kappa &amp;lt; 0.75, good agreement; kappa &amp;lt; 0.4, poor agreement Nevirapine and" exact="tipranavir" post="(Boehringer Ingelheim, http://www.boehringer-ingelheim.com) Saquinavir (Roche, http//www.roche.com) Amprenavir (Glaxo Wellcome,"/>
  <result pre="Adverse effects NRTIs Zidovudine Anemia, nausea, rash, myopathy, dyslipidemia Stavudine," exact="didanosine" post="Nausea, lipoatrophy, dyslipidemia, pancreatitis, lactic acidosis, hepatic steatosis Abacavir"/>
  <result pre="dyslipidemia, diarrhea, insulin resistance Atazanavir Jaundice, sclera icterus, nephrolithiasis Lopinavir," exact="fosamprenavir" post="Heart disease Integrase inhibitors Raltegravir Headache, insomnia, dizziness, fatigue"/>
  <result pre="analogue mutations. Associated with resistance to most nucleoside analogue except" exact="lamivudine" post="M41L, D67N In vitro cause high-level resistance to zidovudine"/>
  <result pre="except lamivudine M41L, D67N In vitro cause high-level resistance to" exact="zidovudine" post="and low-level resistance to stavudine, didanosine, and abacavir K70R,"/>
  <result pre="resistance to zidovudine and low-level resistance to stavudine, didanosine, and" exact="abacavir" post="K70R, L210W Segregate in two pathways, one comprising T215Y"/>
  <result pre="Pathway comprising T215Y and L210W associated with decreased responsiveness to" exact="tenofovir" post="M184V Observed in most viruses resistant to treatment with"/>
  <result pre="tenofovir M184V Observed in most viruses resistant to treatment with" exact="lamivudine" post="Confers high-level resistance to lamivudine in vitro Can interfere"/>
  <result pre="viruses resistant to treatment with lamivudine Confers high-level resistance to" exact="lamivudine" post="in vitro Can interfere with resistance to zidovudine and"/>
  <result pre="resistance to lamivudine in vitro Can interfere with resistance to" exact="zidovudine" post="and stavudine when the number of thymidine analogue mutations"/>
  <result pre="lamivudine in vitro Can interfere with resistance to zidovudine and" exact="stavudine" post="when the number of thymidine analogue mutations is small"/>
  <result pre="analogue mutations is small Increase the level of resistance to" exact="didanosine" post="and abacavir owing to thymidine analogue mutations Q151M Rare"/>
  <result pre="is small Increase the level of resistance to didanosine and" exact="abacavir" post="owing to thymidine analogue mutations Q151M Rare pathway for"/>
  <result pre="In vitro, cause high-level resistance to most nucleoside analogues except" exact="lamivudine" post="and tenofovir 69 Insertional mutations Insertion of two or"/>
  <result pre="cause high-level resistance to most nucleoside analogues except lamivudine and" exact="tenofovir" post="69 Insertional mutations Insertion of two or more amino"/>
  <result pre="all nucleoside analogues K65R Selected for by zalcitabine, abacavir, and" exact="tenofovir" post="therapy Y115F Selected for by abacavir therapy L74V Selected"/>
  <result pre="by zalcitabine, abacavir, and tenofovir therapy Y115F Selected for by" exact="abacavir" post="therapy L74V Selected for by didanosine therapy, usually when"/>
  <result pre="Y115F Selected for by abacavir therapy L74V Selected for by" exact="didanosine" post="therapy, usually when didanosine is the only nucleoside analogue"/>
  <result pre="abacavir therapy L74V Selected for by didanosine therapy, usually when" exact="didanosine" post="is the only nucleoside analogue Mutations conferring resistance to"/>
  <result pre="resistance to NNRTIs K103N Mutation most frequently selected for by" exact="efavirenz" post="therapy Occasionally selected for by nevirapine therapy Confers high-level"/>
  <result pre="frequently selected for by efavirenz therapy Occasionally selected for by" exact="nevirapine" post="therapy Confers high-level resistance to all available NNRTIs Y181C"/>
  <result pre="to all available NNRTIs Y181C Mutations most frequently selected by" exact="nevirapine" post="Y188C Confers high-level resistance to nevirapine but lower-level resistance"/>
  <result pre="most frequently selected by nevirapine Y188C Confers high-level resistance to" exact="nevirapine" post="but lower-level resistance to efavirenz Y108I Y188L, unlike Y188C,"/>
  <result pre="Y188C Confers high-level resistance to nevirapine but lower-level resistance to" exact="efavirenz" post="Y108I Y188L, unlike Y188C, seen mostly with efavirenz therapy"/>
  <result pre="resistance to efavirenz Y108I Y188L, unlike Y188C, seen mostly with" exact="efavirenz" post="therapy L100I, V106A, G190A, G190S Mutations that accumulate during"/>
  <result pre="with most protease inhibitors Mutation most frequently selected for by" exact="saquinavir" post="therapy V82A, V82T, V82F Common resistance mutations Can emerge"/>
  <result pre="with most protease inhibitors Mutations most frequently selected for by" exact="ritonavir" post="and indinavir therapy D30N Mutations most frequently selected for"/>
  <result pre="protease inhibitors Mutations most frequently selected for by ritonavir and" exact="indinavir" post="therapy D30N Mutations most frequently selected for by nelfinavir"/>
  <result pre="and indinavir therapy D30N Mutations most frequently selected for by" exact="nelfinavir" post="therapy N88D, N88S D30N always first L101, L10F, K20R,K20M,"/>
  <result pre="resistance to most protease inhibitors G48V Exclusively selected for by" exact="saquinavir" post="therapy Associated with high-level resistance to saquinavir L24I Emerges"/>
  <result pre="selected for by saquinavir therapy Associated with high-level resistance to" exact="saquinavir" post="L24I Emerges occasionally during failure of indinavir therapy Also"/>
  <result pre="high-level resistance to saquinavir L24I Emerges occasionally during failure of" exact="indinavir" post="therapy Also found with lopinavir therapy I47V, I50V Most"/>
  <result pre="Emerges occasionally during failure of indinavir therapy Also found with" exact="lopinavir" post="therapy I47V, I50V Most often selected for by amprenavir"/>
  <result pre="with lopinavir therapy I47V, I50V Most often selected for by" exact="amprenavir" post="therapy Also found with lopinavir therapy V32I, F53L Rare"/>
  <result pre="Most often selected for by amprenavir therapy Also found with" exact="lopinavir" post="therapy V32I, F53L Rare mutations Confer high-level resistance to"/>
  <result pre="analogues Same as nucleoside analogues K65 R impairs incorporation of" exact="tenofovir" post="into DNA thymidine analogue mutations often associated with cross-resistance"/>
  <result pre="into DNA thymidine analogue mutations often associated with cross-resistance to" exact="tenofovir" post="Tenofovir Nucleoside reverse transcriptase inhibitors Bind a hydrophobic pocket"/>
  <result pre="transcriptase and is the main mutation that confers resistance to" exact="lamivudine" post="(Boucher et al. 1993). Methionine 184 is located at"/>
  <result pre="a different side chain, interferes with the proper positioning of" exact="lamivudine" post="triphosphate within the catalytic site (Sarafianos et al. 1999)."/>
  <result pre="mutation induces very high levels of resistance to lamivudine. When" exact="lamivudine" post="is used as a single agent, resistant strains overtake"/>
  <result pre="in a few weeks (Schuurman et al. 1995), and when" exact="lamivudine" post="is used as part of a failing regimen of"/>
  <result pre="for in the course of the failure of regimens containing" exact="stavudine" post="and didanosine. This pathway always starts with the Q151M"/>
  <result pre="can confer high-level resistance to most but not all (e.g.," exact="lamivudine" post="and tenofovir) analogues (Iversen et al. 1996). Interestingly, the"/>
  <result pre="nucleoside or nucleotide analogues fails, especially when the regimen includes" exact="tenofovir" post="or abacavir. This mutation appears to confer resistance to"/>
  <result pre="failure of drug combinations that include thymidine analogues, such as" exact="zidovudine" post="and stavudine, but they can promote resistance to almost"/>
  <result pre="promote resistance to almost all nucleoside and nucleotide analogues, including" exact="tenofovir" post="(Larder and Kemp 1989; Picard et al. 2001). These"/>
  <result pre="most frequently are somewhat drug dependent (Table 28.12). Resistance to" exact="nevirapine" post="is often associated with the Y181C mutation, but other"/>
  <result pre="Y188C, K103N, G190A, and V106A, also occur. Initial resistance to" exact="efavirenz" post="is generally characterized by the K103N mutation, but the"/>
  <result pre="HR1 and blocks the infectivity of HIV-1. Viral resistance to" exact="enfuvirtide" post="usually results from mutations located in a stretch of"/>
  <result pre="probably explain the remarkably wide range of natural susceptibility to" exact="enfuvirtide" post="among HIV-1 strains (Derdeyn et al. 2001; Reeves et"/>
  <result pre="Gilead Sciences (Borroto-Esoda et al. 2004). Study FTC-301A compared once-daily" exact="emtricitabine" post="(Emtriva) to once-daily stavudine (Zerit), both combined with didanosine"/>
  <result pre="al. 2004). Study FTC-301A compared once-daily emtricitabine (Emtriva) to once-daily" exact="stavudine" post="(Zerit), both combined with didanosine (Videx) and efavirenz (Sustiva),"/>
  <result pre="once-daily emtricitabine (Emtriva) to once-daily stavudine (Zerit), both combined with" exact="didanosine" post="(Videx) and efavirenz (Sustiva), in 571 treatment-naïve patients from"/>
  <result pre="to once-daily stavudine (Zerit), both combined with didanosine (Videx) and" exact="efavirenz" post="(Sustiva), in 571 treatment-naïve patients from North America, Latin"/>
  <result pre="the incidence of virologic failure was 12 % in the" exact="stavudine" post="group and 5 % in the emtricitabine group. Among"/>
  <result pre="% in the stavudine group and 5 % in the" exact="emtricitabine" post="group. Among patients with drug-resistant virus at baseline, virologic"/>
  <result pre="at baseline, virologic failure occurred in 32 % of the" exact="stavudine" post="group and 13 % of the emtricitabine group. Mutations"/>
  <result pre="% of the stavudine group and 13 % of the" exact="emtricitabine" post="group. Mutations The K65R Mutation Perhaps the most widely"/>
  <result pre="In this study, 345 patients were randomized to receive either" exact="tenofovir" post="or efavirenz, combined with a fixed-dose combination tablet containing"/>
  <result pre="efavirenz, combined with a fixed-dose combination tablet containing 600 mg" exact="abacavir" post="and 300 mg lamivudine, all to be taken once"/>
  <result pre="5.4 % patients in the efavirenz-based arm. Tenofovir, abacavir, and" exact="lamivudine" post="can all select for the K65R mutation. Among 21"/>
  <result pre="10 (48 %) had the K65R mutation. Tenofovir, abacavir, and" exact="lamivudine" post="all exert concerted pressure on the 65 locus, and,"/>
  <result pre="is believed to be the primary mechanism of resistance to" exact="zidovudine" post="and stavudine, the process is not drug specific in"/>
  <result pre="drug binding and incorporation; there are data suggesting that concurrent" exact="zidovudine" post="use can prevent the emergence of the K65R mutation"/>
  <result pre="initiating therapy for the first time, tenofovir-inclusive regimens not involving" exact="zidovudine" post="were much more likely to fail in association with"/>
  <result pre="addition of a second protease inhibitor to a regimen containing" exact="amprenavir" post="(Agenerase) improved the 24-week response to salvage therapy (Mellors"/>
  <result pre="amprenavir. In addition, subjects were randomized to receive either placebo," exact="nelfinavir" post="(Viracept), saquinavir (Fortovase), or indinavir (Crixivan). There were no"/>
  <result pre="addition, subjects were randomized to receive either placebo, nelfinavir (Viracept)," exact="saquinavir" post="(Fortovase), or indinavir (Crixivan). There were no statistically significant"/>
  <result pre="randomized to receive either placebo, nelfinavir (Viracept), saquinavir (Fortovase), or" exact="indinavir" post="(Crixivan). There were no statistically significant differences between the"/>
  <result pre="common TAM pattern and is associated with high-level resistance to" exact="zidovudine" post="and with cross-resistance to other NRTIs, including tenofovir and"/>
  <result pre="resistance to zidovudine and with cross-resistance to other NRTIs, including" exact="tenofovir" post="and abacavir. In contrast, the D67N/K70R/K219Q pathway isolate is"/>
  <result pre="there was a substantial growth advantage in the presence of" exact="zidovudine" post="(Hu et al. 2004). Thus, it was concluded that"/>
  <result pre="T215Y pathway is more common and confers higher-level resistance to" exact="zidovudine" post="and other NRTIs, whereas viruses carrying T215F have lower"/>
  <result pre="confers a significant advantage to HIV in the presence of" exact="zidovudine" post="and that this mutation plays a much larger role"/>
  <result pre="mutation plays a much larger role in the development of" exact="zidovudine" post="resistance than is usually considered (Kuritzkes 2004). Perhaps the"/>
  <result pre="is M184V, which is known to cause high-level resistance to" exact="lamivudine" post="and emtricitabine. However, there have been studies suggesting that"/>
  <result pre="However, there have been studies suggesting that high-level resistance to" exact="lamivudine" post="does not necessarily mean that the drug is rendered"/>
  <result pre="terms of maintaining the less-fit virus. One more study discontinued" exact="lamivudine" post="in four highly treatment-experienced patients with no viable alternative"/>
  <result pre="us that, even in the presence of the M184V mutation," exact="lamivudine" post="was still contributing to HIV RNA suppression. Reversion of"/>
  <result pre="increase in viral load of 0.3 log10 copies/ml. Upon resuming" exact="lamivudine" post="therapy, the M184V mutation reappeared within 8 weeks in"/>
  <result pre="regimen, approximately half of the patients were randomized to continue" exact="lamivudine" post="therapy, with the remaining patients randomized to discontinue lamivudine"/>
  <result pre="continue lamivudine therapy, with the remaining patients randomized to discontinue" exact="lamivudine" post="treatment. Forty-eight weeks later, there were no significant differences"/>
  <result pre="in CYP2B6 signals a longer half-life and increased levels of" exact="efavirenz" post="(Haas et al. 2004). Other haplotypes within CYP2B6 have"/>
  <result pre="within CYP2B6 have been associated with a longer half-life for" exact="nevirapine" post="(Chantarangsu 2009). The genetic variant associated with Gilbert’s disease,"/>
  <result pre="genotype as a predictor of virological failure in patients receiving" exact="emtricitabine" post="once daily or stavudine twice daily in combination with"/>
  <result pre="of virological failure in patients receiving emtricitabine once daily or" exact="stavudine" post="twice daily in combination with didanosine and efavirenz [Abstract"/>
  <result pre="emtricitabine once daily or stavudine twice daily in combination with" exact="didanosine" post="and efavirenz [Abstract 672]. In: 11th conference on retroviruses"/>
  <result pre="daily or stavudine twice daily in combination with didanosine and" exact="efavirenz" post="[Abstract 672]. In: 11th conference on retroviruses and opportunistic"/>
  <result pre="Young RK, Johnson SC et al (2003) Antiviral activity of" exact="lamivudine" post="in persons infected with HIV-1 that has M184V and"/>
  <result pre="takeover of YMDD motif mutant hepatitis B virus during long-term" exact="lamivudine" post="therapy and re-takeover by wild type after cessation of"/>
  <result pre="open-label, multi-center trial to evaluate safety and efficacy of continued" exact="lamivudine" post="twice daily versus discontinuation of lamivudine in HIV-1-infected adults"/>
  <result pre="and efficacy of continued lamivudine twice daily versus discontinuation of" exact="lamivudine" post="in HIV-1-infected adults with virological failure on ongoing combination"/>
  <result pre="Rodriguez AE, Weinberg W et al (2003) Early non-response to" exact="tenofovir" post="DF (TDF) + abacavir (ABC) and lamivudine (3TC) in a randomized"/>
  <result pre="al (2003) Early non-response to tenofovir DF (TDF) + abacavir (ABC) and" exact="lamivudine" post="(3TC) in a randomized trial compared to efavirenz (EFV) + ABC"/>
  <result pre="(ABC) and lamivudine (3TC) in a randomized trial compared to" exact="efavirenz" post="(EFV) + ABC and 3TC: ESS30009[Abstract 1722a]. In: 43rd interscience conference"/>
  <result pre="genomics to emerging zoonotic viral diseasesPLoS Pathog2009510e100055719855817 HaasDRibaudoHKimRet al.Pharmacogenetics of" exact="efavirenz" post="and central nervous system side effectsAIDS2004182391240015622315 HannaGJD’AquilaRTClinical use of"/>
  <result pre="hepatitis B patients: a pilot studyHepatology2002361416142412447867 KleinTEet al.Estimation of the" exact="warfarin" post="dose with clinical and pharmacogenetic dataN Engl J Med200936075376419228618"/>
  <result pre="LarderBAKempSDMultiple mutations in HIV-1 reverse transcriptase confer high-level resistance to" exact="zidovudine" post="(AZT)Science1989246115511582479983 LarderBAKempSDHarriganPRPotential mechanism for sustained antiretroviral efficacy of AZT-3TC"/>
  <result pre="infectionJ Virol20057918116931170416140747 McHutchisonJGGordonSCSchiffERet al.Interferon alfa-2b alone or in combination with" exact="ribavirin" post="as initial treatment for chronic hepatitis C. Hepatitis Interventional"/>
  <result pre="human immunodeficiency virus type 1 isolates from patients treated with" exact="stavudine" post="and didanosine or zidovudine and lamivudineJ Infect Dis200118478178411517441 PichoudCSeigne`resBWangZTrepoCZoulimFTransient"/>
  <result pre="virus type 1 isolates from patients treated with stavudine and" exact="didanosine" post="or zidovudine and lamivudineJ Infect Dis200118478178411517441 PichoudCSeigne`resBWangZTrepoCZoulimFTransient selection of"/>
  <result pre="1 isolates from patients treated with stavudine and didanosine or" exact="zidovudine" post="and lamivudineJ Infect Dis200118478178411517441 PichoudCSeigne`resBWangZTrepoCZoulimFTransient selection of a hepatitis"/>
  <result pre="polymerase gene mutant associated with a decreased replication capacity and" exact="famciclovir" post="resistanceHepatology1999292302379862871 Pirmohamed M (2001) The pharmacogenomics of HIV therapy."/>
  <result pre="RamseyLBet al.Rare versus common variants in pharmacogenetics: SLCO1B1 variation and" exact="methotrexate" post="dispositionGenome Res2012221822147369 RauchAKutalikZDescombesPet al.Genetic variation in IL28B is associated"/>
  <result pre="persistence and cervical precancer/cancerPLoS One201274e3361922496757 SagreiyaHet al.Extending and evaluating a" exact="warfarin" post="dosing algorithm that includes CYP4F2 and pooled rare variants"/>
  <result pre="Acad Sci USA199996100271003210468556 SchapiroJMWintersMALawrenceJMeriganTCClinical cross-resistance between the HIV-1 protease inhibitors" exact="saquinavir" post="and indinavir and correlations with genotypic mutationsAIDS19991335936510199226 SchiffmanMCastlePEJeronimoJRodriguezACWacholderSHuman papillomavirus"/>
  <result pre="USA199996100271003210468556 SchapiroJMWintersMALawrenceJMeriganTCClinical cross-resistance between the HIV-1 protease inhibitors saquinavir and" exact="indinavir" post="and correlations with genotypic mutationsAIDS19991335936510199226 SchiffmanMCastlePEJeronimoJRodriguezACWacholderSHuman papillomavirus and cervical"/>
  <result pre="and appearance of drug-resistant virus populations in persons treated with" exact="lamivudine" post="(3TC)J Infect Dis1995171141114197539472 Shafer, R (2003) Human immunodeficiency virus"/>
  <result pre="al.First large, multicenter, open label study utilizing HLA-B*5701 screening for" exact="abacavir" post="hypersensitivity in North AmericaAIDS2008221673167518670229 StevensWHorsfieldPScottLEEvaluation of the performance of"/>
  <result pre="is associated with response to chronic hepatitis C interferon-alpha and" exact="ribavirin" post="therapyNat Genet200941101100110419749758 TanakaYNishidaNSugiyamaMet al.Genome-wide association of IL28B with response"/>
  <result pre="al.Genome-wide association of IL28B with response to pegylated interferon-a and" exact="ribavirin" post="therapy for chronic hepatitis CNat Genet20091011051111 ThioCLThomasDLInterleukin-28b: a key"/>
  <result pre="interferon alpha pathway genes and response to pegylated interferon-Alpha2a plus" exact="ribavirin" post="for treatment of chronic hepatitis C virus infection in"/>
 </snippets>
</snippetsTree>
